Nebido (Testosterone Undecanoate)

Testosterone undecanoate is a long‑acting prodrug that is hydrolyzed after intramuscular injection to release testosterone. The active hormone binds to androgen receptors in target tissues, influencing gene expression and producing anabolic and androgenic effects that normalize male hormonal function.

The dosing regimen for Nebido is individualized by the prescribing healthcare professional based on the patient’s clinical condition, baseline testosterone levels, and response to therapy. Only a qualified prescriber should determine the appropriate dose and injection interval.

Nebido is not intended for use in women, and safety data for pregnancy or breastfeeding are lacking. It is contraindicated in women of child‑bearing potential unless effective contraception is used, and it should not be administered to nursing mothers.

To place an order, submit an enquiry on the Nebido product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Nebido offers a long‑acting formulation that typically requires only two injections per year, reducing the frequency of clinic visits compared with shorter‑acting testosterone esters that may need weekly or bi‑weekly dosing. This extended dosing interval can improve patient convenience and adherence while maintaining stable serum testosterone levels.

Nebido should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the vial from direct light, moisture and extreme temperature fluctuations. Do not freeze the product, and handle it with aseptic technique when preparing for intramuscular injection.

Nebido is administered as an intramuscular injection, usually into the gluteal muscle, by a qualified healthcare professional. The injection is given as a deep intramuscular depot, allowing the testosterone undecanoate to be released slowly over several months.

Serious risks include polycythemia, which can increase the chance of blood clots; cardiovascular events such as myocardial infarction or stroke; and potential exacerbation of prostate disease. Patients should be monitored regularly for hematocrit levels, cardiovascular health, and prostate-specific antigen (PSA) changes.

Nebido is contraindicated in men with known or suspected prostate or breast cancer, severe untreated sleep apnea, uncontrolled heart failure, or those who have experienced allergic reactions to testosterone undecanoate or any component of the formulation.